The BEZ235 dual PI3K/mTOR inhibitor has been reported to exhibit excellent anti-cancer effects in many types of cancer including melanoma, colorectal, lung, renal, breast, and prostate cancer [129,130,131,132,133,134]. Here, PIK3CA is linked to cancer.